Last reviewed · How we verify
Insulin glargine, 100 U/ml
Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization while suppressing hepatic glucose production.
Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin glargine, 100 U/ml |
|---|---|
| Also known as | Lantus |
| Sponsor | Sanofi |
| Drug class | Long-acting basal insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin glargine is a recombinant human insulin analog modified to have an extended duration of action (up to 24 hours), providing steady basal insulin coverage. It binds to the insulin receptor on target tissues (muscle, adipose, liver) to facilitate glucose transport into cells and inhibit gluconeogenesis. This mimics the physiological basal insulin secretion pattern in non-diabetic individuals.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment (PHASE4)
- A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) (PHASE3)
- Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients (PHASE3)
- A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections (PHASE3)
- Degludec Glargine U300 Hospital Study (NA)
- Gan & Lee Insulin Glargine Target Type (1) Evaluating Research (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin glargine, 100 U/ml CI brief — competitive landscape report
- Insulin glargine, 100 U/ml updates RSS · CI watch RSS
- Sanofi portfolio CI